Candriam S.C.A. Cyma Bay Therapeutics, Inc. Transaction History

Candriam S.C.A.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Jan 21, 2020	SELL	$1.33 - $5.93 $449,540 - $2 Million	-338,000 Closed	0 $0
Q3 2019 Oct 21, 2019	SELL	$5.12 - $7.21 $204,800 - $288,400	-40,000 Reduced 10.58%	338,000 $2,000
Q2 2019 Aug 01, 2019	SELL	$6.05 - $13.66 $3.63 Million - $8.2 Million	-600,000 Reduced 61.35%	378,000 $2.7 Million
Q4 2018 Feb 14, 2019	BUY	$6.54 - $11.74 $130,800 - $234,800	20,000 Added 2.09%	978,000 $7.7 Million
Q3 2018 Nov 07, 2018	BUY	$10.88 - $14.52 $5.31 Million - $7.09 Million	488,000 Added 103.83%	958,000 $10.6 Million
Q2 2018 Aug 14, 2018	BUY	$10.66 - $14.38 $2.4 Million - $3.24 Million	225,000 Added 91.84%	470,000 $6.31 Million
Q1 2018 May 09, 2018	BUY	$9.0 - $15.16 $990,000 - $1.67 Million	110,000 Added 81.48%	245,000 $3.18 Million
Q4 2017 Feb 07, 2018	BUY	$7.67 - $9.31 $1.04 Million - $1.26 Million	135,000	135,000 $1.24 Million

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.